NewAmsterdam Pharma Company N.V.NewAmsterdam Pharma Company N.V.NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

No trades
See on Supercharts

NAMS fundamentals

NewAmsterdam Pharma Company N.V. financial statements, including revenue, expenses, profit, and loss

The total revenue of NAMS for the last quarter is 29.11 M USD, and it's 1177.36% higher compared to the previous quarter. The net income of Q3 24 is -16.65 M USD.

Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q1 '24
Q2 '24
Q3 '24
TTM
Total revenueYoY growth
Gross profitYoY growth
Pretax incomeYoY growth
Net incomeYoY growth
EBITDAYoY growth
EBITYoY growth